Catalent, Inc and the Cell and Gene Therapy Catapult (CGT Catapult) are to collaborate in designing and delivering two training courses focused on medicines manufacturing processes. These courses aim to help the advanced therapies sector ensure its workforce is up-to-date and informed of the latest innovations, processes and best practices within an industry that requires increasing automation and digitalisation.
Drawing on the collective expertise of both organisations, the two courses will focus on derisking the manufacturing process and exploring the principles of gap analysis and risk assessment in a manufacturing workflow.
Catalent is a New Jersey-based global leader in enabling the development and supply of better treatments for patients worldwide. It is an industry-leading technology, development, and manufacturing partner for advanced therapeutics and aims to support innovators in bringing life enhancing therapies to patients.
The training courses will take place at the CGT Catapult’s state-of-the-art Skills and Training Laboratories based in Stevenage.
“We are delighted to be working with Catalent, drawing on its extensive experience in manufacturing cell and gene therapies to design and deliver these new courses, and support the advanced therapies industry to ensure its workforce is equipped with the latest industry knowledge and techniques.”
Stephen Ward, Chief Technology Officer
“Catalent is dedicated to delivering life-saving cell and gene therapies to patients, and having a skilled work force in the advanced therapies space is a key pillar to achieve this. We are excited to be partnering with the CGT Catapult, an organisation who shares our passion for accelerating advanced therapies, on this initiative.”
Delara Motlagh, Vice President, Global Cell Therapy and Plasmid DNA, Catalent
